Preclinical data reproducibility for R&D - The challenge for neuroscience

Psychopharmacology

Volumn 232, Issue 2, 2015, Pages 317-320

  Steckler, Thomas ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; DRUG INDUSTRY; FRAUD; FUNDING; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; NEUROSCIENCE; PRIORITY JOURNAL; PROFESSIONAL MISCONDUCT; PUBLICATION; PUBLISHING; REPRODUCIBILITY; REVIEW; ANIMAL; DRUG SCREENING; PROCEDURES; STANDARDS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; NEUROSCIENCES; REPRODUCIBILITY OF RESULTS;

EID: 84926450571     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3836-3     Document Type: Review

References (44)

1. Anderson DC, Kodukula K (2014) Biomarkers in pharmacology and drug discovery. Biochem Pharmacol 87:172-188
2. Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483:531-533
3. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafo MR (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14:365-376
4. Chalmers I, Glasziou P (2009) Avoidable waste in the production and reporting of research evidence. Lancet 374:86-89
5. Cyranoski D (2013) China drugs head fired over article row. Nature 498:283
6. Fang FC, Steen RG, Casadevall A (2012) Misconduct accounts for the majority of retracted publications. Proc Natl Acad Sci USA 109:17028-17033
7. Fanelli D (2009) How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS One 4:e5738
8. Fitz NF, Cronican AA, Lefterov I, Koldamova R (2013) Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 340:924
9. Franco A, Malhotra N, Simonovits G (2014) Publication bias in the social sciences: unlocking the file drawer. Science 345:1502-1505
10. Frantz S (2004) Therapeutic area influences drug development costs. Nat Rev Drug Disc 3:466-467
11. Ioannidis JPA (2005) Why most published research findings are false. PLoS Med 2:e124
12. Ioannidis JPA (2014) How to make more published research true. PLoS Med 11:e1001747
13. Kilkenny C, Parsons N, Kadyszewski E, Festing MFW, Cuthill IC, Fry D, Hutton J, Altman DG (2009) Survey of the quality of experimental design, statistical analysis and experimental reporting of research using animals. PLoS One 11:e7824
14. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Disc 3:711-715
15. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187-191
16. Lazzeroni LC, Lu Y, Belitskaya-Levy I (2014) P-values in genomics: apparent precision masks high uncertainty. Mol Psychiatry. doi:10. 1038/mp. 2013.184
17. Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Khan AW, Glasziou P (2014) Biomedical research: increasing value, reducing waste. Lancet 383:101-104
18. McNutt M (2014) Journals unite for reproducibility. Science 346:678
19. Mehta J (2011) Preclinical Outsourcing Report: Long-term and more collaborative contracts to optimize cost structures. Contract Pharma
20. Michalek AM, Hutson AD, Wicher CP, Trump DL (2010) The costs and underappreciated consequences of research misconduct: a case study. PLoS Med 7:e1000318
21. Mobley A, Linder SK, Braeuer R, Ellis LM, Zwelling L (2013) A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLoS One 8:e63221
22. Moris F, Shackelford B (2014) Extramural R&D funding by U. S.-located businesses nears $30 billion in 2011. InfoBrief, NSF 14-314
23. Motulsky HJ (2014) Common misconceptions about data analysis and statistics. Naunys Schmiedebergs Arch Pharmacol. doi:10.1007/s00210-014-1037-6
24. Nature Editorial (2013) Reducing our irreproducibility. Nature 496:398 (go.nature.com/oloeip)
25. Nature Editorial (2014) Journals unite for reproducibility. Nature 515:7
26. Nature Medicine Opinions (2013) The yearbook. Nat Med 19:1561
27. Normile D (2014) Rieken shrinks troubled center. Science 345:1110
28. Nuzzo R (2014) Statistical errors. Nature 506:150-152
29. O'Boyle EH Jr, Banks GC, Gonzalez-Mule E (2014) The chrysalis effect: how ugly initial results metamorphosize into beautiful articles. J Air Waste Manage Assoc. doi:10.1177/0149206314527133
30. Peers IS, Ceuppens PR, Harbron C (2012) In search of preclinical robustness. Nat Rev Drug Disc 11:733-734
31. Peers IS, South MC, Ceuppens PR, Bright JD, Pilling E (2014) Can you trust your animal study data? Nat Rev Drug Disc 13:560
32. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DA, Golde TE, Felsenstein KM (2013) Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 340:924
33. Prinz F, Schlange T, Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Disc 10:712
34. Schooler JW (2014) Metascience could rescue the 'replication crisis'. Nature 515:9
35. Selyukh A, Yukhananov A (2011) FDA finds U. S.drug research firm faked documents. Reuters
36. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B (2013) Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 340:924
37. The Economist (2013) Unreliable research: trouble at the lab. Economist 26-30
38. Tsilidis KK, Panagiotou OA, Sena ES, Aretoula E, Evangelou E, Howells DW, Salman RA-S, Macleod MR, Ioannidis JPA (2013) Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 11:e1001609
39. Van Noorden R (2011) The trouble with retractions. Nature 478:26-28
40. Van Noorden R (2014) Irish university labs face external audits. Nature 510:325
41. Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, La Rocca GM, Haendel MA (2013) On the reproducibility of science: unique identification of research resources in the biomedical literature. Peer J 1:e148
42. Wahlsten D (2001) Standardizing tests of mouse behavior: reasons, recommendations, and reality. Physiol Behav 73:695-704
43. Wahlsten D, Rustay NR, Metten P, Crabbe JC (2003) In search of a better mouse test. Trends Neurosci 26:132-136
44. Wellcome Trust (2013) Wellcome Trust Grant Conditions